Although several risk stratification systems are currently in use for the management of prostate cancer, including those based on prostate-specific antigen (PSA), Gleason score, or the tumor stage, up to 40% of the patients undergoing RP eventually experience biochemical recurrence (BCR) and need additional treatment2, 3. This evidence concerns the gene KLK3 and neoplasm.